title: [Treatment of bronchitis with cefaclor (Panoral) (author's transl)].
abstract: 14 patients from the Allergy Unit of an outpatient clinic suffering from acute exacerbation of chronic bronchitis and 13 outpatients with acute bronchitis were treated with 250 mg cefaclor (Panoral) 3 times daily per os for 5 days. 59% of the organisms isolated from cefaclor-sensitive sputum at the time of prominent clinical symptoms were resistent to tetracycline, 53% of them were resistant to penicillin, and 37% were resistant to ampicillin. 12 out of the 14 patients with acute exacerbation of chronic bronchitis became asymptomatic, and no organisms could be detected in the sputum of 13 out of the same 14 patients two days after cessation of cefaclor treatment. In 12 out of the 13 patients with acute bronchitis, the acute clinical symptoms disappeared and in 11 out of the 13 patients the initial sputum organisms were two days after stopping cefaclor treatment.
mesh_terms: D001991:Bronchitis / Q000188:drug therapy*; D002511:Cephalosporins / Q000627:therapeutic use*; D002908:Chronic Disease; D004341:Drug Evaluation; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006801:Humans; D007709:Klebsiella / Q000187:drug effects; D008297:Male; D013183:Sputum / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects
chemical_list: D002511:Cephalosporins
vernacular_title: Behandlung von Bronchitiden mit Cefaclor (Panoral).